Antitumor activity, distribution, and metabolism of 13-cis-retinoic acid as a single agent or in combination with tamoxifen in established human MCF-7 xenografts in mice

Purpose: The efficacy of 13-cis-retinoic acid (13-CRA) given as a single ag ent or in combination with tamaxifen (TAM) was determined in athymic nude m ice bearing advanced s.c. MCF-7 human breast cancers. Methods: 13-CRA alone was given by gavage at doses ranging from 26.4 to 200 mg/kg. TAM alone was given by gavage at doses of 7.5, 15, 30, or 60 mg/kg. For combination stud ies, each dose of TAM was followed 4 h later by 13-CRA at doses of 25, 50, 100, or 200 mg/kg. All treatments began on day 12 and were continued for 3 weeks. Results: The median time to two doublings recorded for the control a nd for 13-CRA and TAM given as single agents at the highest dose were 22.2, 29.2, and 54.7 days, respectively. In combination, 100 and 200 mg/kg 13-CR A with 7.5 mg/kg TAM resulted in a delay in tumor growth at least as high a s that achieved with highest-dose TAM alone, but the effect was not synergi stic. Pharmacokinetic analysis of 13-CRA was performed in plasma, liver, an d tumor from mice bearing 0.5- to 2.0 g carcinomas following a single dose of 100 mg/kg 13-CRA. Results showed that 13-CRA was metabolized differently in various tissues, but concentrations of 13-CRA detected in tumor were in the range reported to be active in vitro. all-trans-Retinoic acid (ATRA) c oncentrations were about 5% of the 13-CRA concentrations detected in plasma , 68% of those found in liver, and 20% of those found in tumor. 4-oxo-CRA r epresented between 2% and 10% of 13-CRA concentrations detected in plasma a nd liver but was not detected in tumor. Furthermore there was no difference in peak plasma 13-CRA concentrations found in the same tissues at 30 min a fter a single dose or after the eighth doss of 100 mg/kg 13-CRA or 13-CRA a nd TAM. Mean 13-CRA concentrations detected in liver and tumor were 50-90% and 16-30% of plasma peak concentrations, respectively. No difference in 4- oxo-CRA concentration was observed between the treatment groups. Conclusion s: These data suggest that 13-CRA is not effective against established huma n breast tumor xenografts despite the stability of the pharmacokinetics of Ij-CRA and the generation of ATRA as a metabolite. The addition of 13-CRA t o TAM did not improve the efficacy of TAM against these estrogen-receptor-p ositive xenografts.